Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers

The Motherisk Program, Department of Pediatrics, Hospital for Sick Children, and Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Journal of Obstetrics and Gynaecology (Impact Factor: 0.55). 08/2011; 31(6):465-72. DOI: 10.3109/01443615.2011.579197
Source: PubMed


Studies of 1st trimester exposure to ACE inhibitors and angiotensin receptor blockers examining teratogenicity have shown conflicting results. We systematically reviewed the literature and performed a meta-analysis evaluating the risk of major malformations. For the meta-analysis, we included studies comparing 1st trimester exposure to no exposure, or to exposure to other antihypertensives. Additionally, we conducted a qualitative analysis of studies that did not meet the inclusion criteria for the meta-analysis. A significant risk ratio was found when the exposed group was compared with healthy controls but not when compared with other antihypertensives. The qualitative analysis did not demonstrate a specific pattern of major malformations. Our results suggest that 1st trimester exposure to ACE inhibitors and angiotensin receptor blockers is not associated with an elevated risk of major malformations compared with other antihypertensives. A 1st trimester exposure to antihypertensives in general may be associated with an elevated risk of major malformations.

28 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A study by Li and coworkers demonstrates that antihypertensive-drug use and untreated hypertension in pregnancy increase the risk of congenital malformations. Supported by the results of meta-analysis, this study heralds a major shift in our understanding of the fetal risks of hypertension and the medications used to treat this condition.
    No preview · Article · Nov 2011 · Nature Reviews Cardiology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: QUESTION: One of my 35-year-old pregnant patients has been treated with enalapril for primary hypertension. She learned she was pregnant at 11 weeks' gestation. I read somewhere that angiotensin-converting enzyme (ACE) inhibitors can cause malformations. What advice do you give to Motherisk callers? ANSWER: Most published studies have failed to show an effect of ACE inhibitors on congenital malformations. A recent systematic review and meta-analysis conducted by Motherisk does not suggest increased fetal risk of malformations. However, ACE inhibitors should be avoided in late pregnancy, as they might cause renal failure and acalvaria in the baby.
    Full-text · Article · Jan 2012 · Canadian family physician Medecin de famille canadien
  • [Show abstract] [Hide abstract]
    ABSTRACT: The deleterious effects of maternal drug administration on the unborn child are usually considered in terms of teratogenicity. However, few prescribers are aware of the effects that some drugs passively received at the end of pregnancy can have on neonatal adaptation. In addition to analgesics administered during labor, some 15 % of pregnant women take chronic treatments. The aim of this report is to examine the possible risks of such " inherited " drug substances, in order to improve neonatal safety. Gestational modifications of drug metabolism are briefly discussed, along with the timing of embryonic and/or fetal drug exposure and the characteristics of placental drug transfer. Vital threats include effects on the central nervous system, respiration, and hemodynamics. The fetal and neonatal impacts of the main pharmacological categories are summarized, distinguishing those that are strongly contraindicated from those that can be used safely, with caution, during pregnancy. The French National Academy of Medicine stresses the need for specific warnings for healthcare professionals on neonatal hazards of intrauterine drug exposure. This information must be part of the curriculum for medical students of all specialties, and must be underlined by drug companies and regulatory authorities. It should notably be provided through websites such as the Paris Teratogenicity Reference Center (Centre de référence sur les agents tératogènes, CRAT).
    No preview · Article · Mar 2012 · Bulletin de l'Académie nationale de médecine
Show more